Tag Archives: reverses

Escape From Tarkov developer reverses course on limited-time PvE access – PCGamesN

  1. Escape From Tarkov developer reverses course on limited-time PvE access PCGamesN
  2. Tarkov studio claims it actually doesn’t have the server capacity for everyone who paid $150 to play its upcoming PvE mode, still wants players to pay extra PC Gamer
  3. Escape from Tarkov devs attempt to put out fire caused by $250 ‘pay to win’ edition by giving everyone access to an exclusive game mode – but only for 6 months Gamesradar
  4. ‘Escape From Tarkov’ EoD Owners Will Get $250 Mode For Free At Launch Forbes
  5. New Escape from Tarkov edition locks PvE, other features behind paywall Polygon

Read original article here

Bungie Reverses Controversial Destiny 2 Weapons ‘Sunsetting’ Measure – IGN

  1. Bungie Reverses Controversial Destiny 2 Weapons ‘Sunsetting’ Measure IGN
  2. Remember all those Destiny 2 guns you deleted after they got sunset? Bungie admits you shouldn’t have done that: ‘We regret we have no recovery mechanism’ PC Gamer
  3. Bungie is reversing its decision to sunset your weapons ahead of Destiny 2: The Final Shape Polygon
  4. Destiny 2 is un-sunsetting every gun in the MMO with The Final Shape’s massive Power changes – but Bungie says “we have no recovery mechanism” for deleted ones Gamesradar
  5. ‘Destiny 2’ Just Made Three Of Its Biggest Changes In Series History Forbes

Read original article here

Netanyahu belatedly reverses course on Gallant. If only he’d do the same on autocracy – The Times of Israel

  1. Netanyahu belatedly reverses course on Gallant. If only he’d do the same on autocracy The Times of Israel
  2. `We will continue to work together’, says Israel PM Netanyahu after reinstating his defence minister WION
  3. Netanyahu reverses decision to fire Israel defence minister after protests The Guardian
  4. Netanyahu reinstates Gallant, blames last coalition for cross-border attacks, terror The Times of Israel
  5. Israel Protests To Save Defense Minister Yoav Gallant From President Netanyahu | #Shorts | Tel Aviv CNN-News18
  6. View Full Coverage on Google News

Read original article here

Dow Jones Reverses Lower Ahead Of Powell Speech; 7 Best Stocks To Buy And Watch

Dow Jones futures were slightly lower in extended trade ahead of Federal Reserve Chairman Jerome Powell’s speech Tuesday. The Dow Jones Industrial Average rallied as many as 305 points Monday before reversing lower.




X



Powell Speech, Inflation Data, Earnings

Fed chief Powell will speak at the Sveriges Riksbank International Symposium on Central Bank Independence in Stockholm, Sweden. His speech is scheduled to start at 9 a.m. ET. Powell’s speech comes on the heels of Friday’s jobs report that saw wage growth cooling much more than expected and workers clocking fewer hours for a second straight month. The data should allow the Fed to further slow its pace of interest-rate hikes.

Consumer inflation data is due out Thursday morning. The CPI is expected to come in unchanged for the month of December and 6.6% higher year over year, per Econoday estimates. According to the CME’s FedWatch tool, traders place a 77% chance of a 25-basis-point rate hike at the next Fed policy meeting in late January/early February.

The 10-year Treasury yield ticked lower to 3.51% Monday, falling for a second straight session.

Jefferies (JEF) reported earnings that met estimates, and sales that topped forecasts. Jefferies shares lost more than 3% in extended trade.

Other companies reporting later this week include KB Home (KBH), Taiwan Semiconductor Manufacturing (TSM), Bank of America (BAC), Citigroup (C) and Wells Fargo (WFC). Dow Jones stocks JPMorgan Chase (JPM) and UnitedHealth Group (UNH) will also report this week.

Stock Market Today

On Monday, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 lost 0.1%. The tech-heavy Nasdaq composite rallied 0.6%. Among exchange traded funds, the Nasdaq 100 tracker Invesco QQQ Trust (QQQ) moved up 0.65% and the SPDR S&P 500 (SPY) inched lower.

Electric-vehicle giant Tesla (TSLA) traded up 5.9% Monday. Among Dow Jones stocks, Apple (AAPL) gained 0.4% and Microsoft (MSFT) rose 1% in today’s stock market.

Deere (DE), IBD Leaderboard stock ELF Beauty (ELF), Rio Tinto (RIO) and IBD SwingTrader stock Super Micro Computer (SMCI) — as well as Dow Jones names Caterpillar (CAT), Chevron (CVX) and Walmart (WMT) — are among the top stocks to buy and watch with the market back in rally mode.

ELF Beauty is an IBD Leaderboard stock. Super Micro is a new IBD SwingTrader idea. Caterpillar and Rio were featured in this week’s recent Stocks Near A Buy Zone column.


4 Top Growth Stocks To Buy And Watch In The Current Stock Market Rally


Dow Jones Futures Today: Oil Prices

Ahead of Tuesday’s opening bell, Dow Jones futures traded 0.3% below fair value, and S&P 500 futures moved down 0.35%. Tech-heavy Nasdaq 100 futures were down 0.4% vs. fair value. Remember that overnight action in Dow Jones futures and elsewhere doesn’t necessarily translate into actual trading in the next regular stock market session.

U.S. oil prices rallied more than 1% Monday, rebounding a bit from last week’s sharp losses. West Texas Intermediate futures traded just below $75 a barrel.


IBD’s latest newsletter, MarketDiem, gives you actionable ideas for stocks, options and crypto right in your inbox.


What To Do In The New Stock Market Rally

Now is an important time to read IBD’s The Big Picture column with the stock market trend back in a “confirmed uptrend” following Friday’s powerful gains in heavy volume, a stark divergence from recent action.

Friday’s positive action in high volume caused the IBD market outlook to shift into a new stock market rally. Nevertheless, it is still an uncertain environment, and exposure should be increased in a measured fashion. Investors should stick to 20% to 40% exposure for now.

(Check out IBD Stock Lists like the IBD 50 and Stocks Near A Buy Zone, for additional stock ideas.)


Five Dow Jones Stocks To Buy And Watch Now


Dow Jones Stocks To Buy And Watch: Caterpillar, Chevron, Walmart

Dow Jones member Caterpillar remains squarely in buy range above a flat base’s 239.95 buy point following Monday’s 0.9% decline, according to IBD MarketSmith pattern recognition. The buy zone goes up to 251.95. Bullishly, the stock’s relative strength line, a key technical indicator, is at new highs. 

CAT stock shows a strong 98 out of a perfect 99 IBD Composite Rating, per the IBD Stock Checkup. The Composite Rating is designed to help investors easily find top growth stocks.

Energy giant Chevron again found stout resistance at its 50-day line, as it continues to build a cup base that has a 189.78 buy point.

Discount retailer Walmart reversed 1.25% lower Monday, falling back below its 50-day line. Shares are building a cup with handle that has a 154.74 buy point and are about 6% away from the latest entry.

Top Stocks To Buy And Watch: Deere, ELF Beauty, Rio, Super Micro

Recent IBD Stock Of The Day Deere is building a flat base with a 448.50 buy point. Shares are approaching their latest buy point, moving up 0.4% Monday.

IBD Leaderboard stock ELF Beauty gave up its 57.03 flat-base entry amid Monday’s 3.9% decline. Shares broke out Friday in big volume, indicating strong institutional demand for the cosmetics leader. The 5% buy zone tops out at 59.88 if the stock is able to regain the entry.

Recent IBD Stock Of The Day Rio Tinto cut gains to just 0.1% Monday, rising still further above a cup with handle’s 73.45 buy point. The buy area runs up to 77.13.

IBD SwingTrader stock Super Micro Computer is rapidly moving up the right side of a short consolidation that has a 95.32 buy point. Shares slashed gains to 0.45% Monday.

Stocks To Buy And Watch In New Stock Market Rally

These are seven top stocks to buy and watch in today’s stock market, including three Dow Jones leaders.

Company Name Symbol Correct Buy Point Type Of Base
Deere (DE) 448.50 Flat base
ELF Beauty (ELF) 57.03 Flat base
Rio Tinto (RIO) 73.45 Cup with handle
Super Micro Computer (SMCI) 95.32 Consolidation
Caterpillar (CAT) 239.95 Flat base
Chevron (CVX) 189.78 Cup base
Walmart (WMT) 154.74 Cup with handle
Source: IBD Data As Of Jan. 9, 2023

Join IBD experts as they analyze leading stocks in the current stock market rally on IBD Live


Tesla Stock

Tesla stock surged nearly 6% Monday, adding to Friday’s upside reversal. Shares remain sharply below their 50- and 200-day lines.

Last week, shares hit a 52-week low at 101.81. Tesla stock closed Monday about 68% off its 52-week high.

Dow Jones Leaders: Apple, Microsoft

Among Dow Jones stocks, Apple shares climbed 0.4% Monday. Last week, the stock hit a new 52-week low price of 124.17. The stock remains around 20% off its 52-week high.

Microsoft stock rallied 1% Monday, adding to Friday’s gains. The software giant is about 30% off its 52-week high and is still just off its 52-week low of 213.43, reached on Nov. 4.

YOU MAY ALSO LIKE:

Top Growth Stocks To Buy And Watch

Learn How To Time The Market With IBD’s ETF Market Strategy

Find The Best Long-Term Investments With IBD Long-Term Leaders

MarketSmith: Research, Charts, Data And Coaching All In One Place

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Read original article here

Dow Jones Reverses Higher As Tesla Stock Hits New Low On Price Target Cuts

The Dow Jones Industrial Average reversed higher Tuesday morning, as global markets struggled following a sudden monetary policy shift by the Bank of Japan. The Dow Jones industrials sit on a four-day losing streak, with Walt Disney and Nike leading the declines. And Tesla stock saw its price target slashed at multiple analyst firms Tuesday.




X



Economic data due out Wednesday include consumer confidence and existing home sales. December’s consumer confidence index is expected to edge higher to a reading of 101.0 vs. November’s 100.2 reading. Meanwhile, the Econoday consensus number sees November’s existing home sales falling further, to an annualized rate of 4.20 million vs. October’s 4.43 million. Both readings are due out at 10 a.m. ET.

Heico (HEI) rallied 1.5% Tuesday after the company posted better-than-expected quarterly earnings and sales results. General Mills (GIS) dropped 4% despite beating Wall Street’s earnings and sales targets.

More earnings reports this week include Micron Technology (MU) and Dow Jones stock Nike (NKE).

Steel Dynamics (STLD) will join the S&P 500 index and Super Micro Computer (SMCI) will join the S&P MidCap 400, effective prior to Thursday’s market open, according to S&P Dow Jones Indices. Steel Dynamics climbed 0.7%, while SMCI stock jumped 6.7% in morning trade.

Electric-vehicle giant Tesla (TSLA) dropped more than 3% Tuesday morning after multiple price-target cuts from Daiwa, Evercore ISI and Mizuho. Dow Jones tech leaders Apple (AAPL) and Microsoft (MSFT) were lower after today’s stock market open.

IBD Leaderboard stock Neurocrine Biosciences (NBIX), KLA (KLAC), O’Reilly Auto Parts (ORLY) and United Rentals (URI) — as well as Dow Jones names Caterpillar (CAT), Home Depot (HD) and UnitedHealth Group (UNH) — are among the top stocks to consider for investor watchlists.

Neurocrine and United Rentals are IBD Leaderboard stocks. UnitedHealth was featured in last week’s Stocks Near A Buy Zone column. Caterpillar and United Rentals were recent IBD Stock Of The Day companies.


IBD’s latest newsletter MarketDiem gives you actionable ideas for stocks, options and crypto right in your inbox


Dow Jones Today: Oil Prices, Treasury Yields

After Tuesday’s opening bell, the Dow Jones Industrial Average moved up 0.2%, and the S&P 500 rose 0.15%. The tech-heavy Nasdaq composite moved up 0.1% in morning action.

U.S. trade largely resisted the selling that battered markets across Asia on Monday, after the Bank of Japan doubled the yield cap on its 10-year bond to 5%. The move sent ripples through global bond markets and caused a sharp rise in the yen. Tokyo’s Nikkei 225 tumbled 2.6%, while Asia’s other leading markets ended broadly lower.

European markets recovered from the early hit and turned mixed near mid-session. U.S. bonds dropped, sending the 10-year yield nine basis points higher, to 3.66%, pointing to a third-straight rally.

Among U.S. exchange-traded funds, the Nasdaq 100 tracker Invesco QQQ Trust (QQQ) fell 0.6% and the SPDR S&P 500 ETF (SPY) moved down 0.3% early Tuesday.

Meanwhile, U.S. oil prices traded up less than 1% Tuesday, but still on pace to add to Monday’s gains. West Texas Intermediate futures rose to nearly $76 a barrel in morning trade. Natural gas prices shed more than 5% in early action, tacking toward a third straight drop after diving 11% on Monday.

Stock Market Rally Under Pressure

On Monday, tech stocks and small caps underperformed once again, dropping the Nasdaq composite 1.5% and the Russell 2000 1.4%. The Dow Jones Industrial Average held up the best, shedding just 0.5%. The S&P 500 lost 0.8%, closing below its 50-day moving average for the second day in a row.

Monday’s The Big Picture column commented, “The fabled Santa Claus rally denotes the period between Christmas and the first two trading days of 2023. The Dow Jones Industrial Average has averaged a 1.38% gain for this period since 1950 while the S&P 500 has averaged 1.32%, according to data compiled by Dow Jones Market Data. Both indexes traded higher around 78% of the time. There are still no signs that buyers are willing to catch falling knives into year’s end, but skepticism may be high enough to ignite a few short squeezes.”

Now is an important time to read IBD’s The Big Picture column amid the ongoing stock market volatility.


Five Dow Jones Stocks To Buy And Watch Now


Dow Jones Stocks To Watch: Caterpillar, Home Depot, UnitedHealth

Dow Jones member Caterpillar continues to trade near a 239.95 buy point in a flat base, according to IBD MarketSmith pattern recognition, in the wake of Monday’s slight fall. Shares found support at the stock’s 21-day exponential moving average and the stock’s relative strength line is edging to new highs. CAT stock inched higher Tuesday.

CAT stock shows a strong 97 out of a perfect 99 IBD Composite Rating, per the IBD Stock Checkup.  

Home improvement retailer Home Depot is about 4% below a cup-with-handle base’s 329.77 buy point after reversing last week’s breakout move. HD stock traded down 1.1% Tuesday morning after Credit Suisse downgraded the stock from outperform to neutral, with the slowing housing market as a key risk.

Health care giant UnitedHealth Group is tracing a flat base that features a 558.20 buy point. Shares are about 6% away from the latest entry after giving up support near their 50-day line last week. UNH stock is now trying to stem its recent slide around the 200-day line. Shares added 0.4% early Tuesday.


4 Top Growth Stocks To Watch In The Current Stock Market Rally


Top Stocks To Watch: KLA, Neurocrine, O’Reilly, United Rentals

Chip equipment leader KLA has been mostly holding up amid the market weakness, and is about 2% under a cup-with-handle’s 392.60 entry after Monday’s modest loss. KLA shares dropped 1% Tuesday.

IBD Leaderboard stock Neurocrine is attempting to find support at its 50-day level amid a two-week losing streak. A strong rebound would be bullish for the stock’s immediate prospects and would likely lead to the formation of a new base. Meanwhile, a sharp breach could mean the stock needs more consolidation. NBIX stock was up 0.9% Tuesday.

O’Reilly Auto Parts is attempting to find support at its 50-day line this week and remains squarely above a 750.98 flat-base entry. A big rebound off the 50-day line could bring a follow-on entry point, but the market uptrend is under pressure right now, which increases the risk of buying stocks. ORLY shares were up 0.1% Tuesday.

United Rentals remains squarely below a 368.04 buy point in a cup-with-handle pattern. Shares are about 5% below the buy point, and further weakness would trigger the 7%-8% loss rule. URI stock was up 0.1% Tuesday.

Stocks To Watch

These are five top stocks to watch in today’s stock market, including three Dow Jones leaders.

Company Name Symbol Correct Buy Point Type Of Base
KLA (KLAC) 392.60 Cup with handle
United Rentals (URI) 368.04 Cup with handle
Caterpillar (CAT) 239.95 Flat base
Home Depot (HD) 329.77 Cup with handle
UnitedHealth (UNH) 558.20 Flat base
Source: IBD Data As Of Dec. 19, 2022

Join IBD experts as they analyze leading stocks in the current stock market rally on IBD Live


Tesla Stock

Tesla stock fell as much as 2.9% Monday before slashing losses to just 0.2%. Shares declined more than 3% Tuesday morning, as the stock saw its price target cut at Daiwa, Evercore ISI and Mizuho. TSLA stock hit a new 52-week low at 144.17.

Daiwa lowered its target from 240 to 177, in part to the “Twitter distraction.” Evercore slashed its target from 300 to 200, citing weaker demand. And Mizuho lowered its target from 330 to 285, due to a challenging global auto market.

On Monday, TSLA stock hit its lowest level since November 2020. Shares closed about 63% off their 52-week high.

Dow Jones Leaders: Apple, Microsoft

Among Dow Jones stocks, Apple shares sold off 1.6% Monday, hitting their lowest level since mid June. AAPL stock finished just off its 52-week low, which was set on June 16 at 129.04. The stock is around 27% off its 52-week high. Shares traded down 1.4% Tuesday.

Microsoft declined 1.7% Monday, as shares looked to find support around their 50-day line amid a three-day losing streak. The software giant remains about 30% off its 52-week high. MSFT stock moved down 0.1% early Tuesday.

Be sure to follow Scott Lehtonen on Twitter at @IBD_SLehtonen for more on growth stocks and the Dow Jones Industrial Average.

YOU MAY ALSO LIKE:

Top Growth Stocks To Buy And Watch

Learn How To Time The Market With IBD’s ETF Market Strategy

Find The Best Long-Term Investments With IBD Long-Term Leaders

MarketSmith: Research, Charts, Data And Coaching All In One Place

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks



Read original article here

DeSantis reverses himself on coronavirus vaccines, moving right of Trump

Comment

Early in the pandemic, Florida Gov. Ron DeSantis repeatedly praised President Donald Trump for the expedited development and rollout of a coronavirus vaccine. The governor’s office pushed for $480 million in pandemic resources, including media campaigns promoting the shots, according to state budget documents. And DeSantis, a Republican, even lauded the Biden administration for helping to expand access to vaccines.

“We’re having more vaccine because of this, which is great,” DeSantis said of a federal program shipping shots to pharmacies in February 2021.

But this past week, DeSantis threw himself into misleadingly disparaging the vaccines, convening skeptics to buck guidance from the Centers for Disease Control and Prevention and seeking to investigate vaccine makers for fraud.

“These companies have made a fortune off this federal government imposing or at least attempting to impose mandates, and a lot of false statements,” DeSantis said at the roundtable event on Wednesday. “I think people want the truth and I think people want accountability, so you need to have a thorough investigation into what’s happened with these shots.”

A review of DeSantis’s public positions on the vaccines shows a full reversal that has unfolded gradually since 2021, seizing on the shots’ waning efficacy against new virus variants and portraying evolving scientific advice as deliberate deceit.

The hard-line position he’s now staking out is taking on additional significance: DeSantis is widely seen as a potential presidential candidate in 2024, with many Republicans wanting him to challenge Trump for the GOP nomination and some seeing vaccines as a potential wedge issue to outflank the former president to his right.

“We know he’s not really anti-vax, he’s on the record, but now he’s taking this position for really blatant political purposes, it appears, and it’s really undermining to health care professionals,” said Dr. David Pate, a retired health systems executive and lifelong Republican who has advised Idaho Gov. Brad Little (R). “I’m not sure what the gain is, because he’s already got the base, and now this is just going to alienate moderates and independents.”

Spokespeople for DeSantis did not respond to detailed questions and requests for comment.

Trump has all but acknowledged his potential vulnerability on the issue of vaccines. He was booed in December 2021 for saying he received a booster shot. Then, at a rally in Alaska in July, he touted his administration’s response to the pandemic while avoiding using the word “vaccine.”

Tensions have grown between the two men as Trump formally announced his 2024 candidacy and DeSantis has risen as a potential rival, with chants of “two more years” at his reelection victory party on Nov. 8. Several early primary polls have shown DeSantis leading Trump; a CNN survey this month found one of the steepest drops in support for Trump’s 2024 bid among voters who describe themselves as very conservative. Skepticism about the vaccines and guidance from government health agencies has been palpable in the far-right wing of the party in recent years.

DeSantis’s event succeeded in drawing cheers from pro-Trump corners of the far-right. “What I like about DeSantis, he’s probably not a guy you’d like to run at, let’s go have a beer, but he’s all business,” former Trump strategist Stephen K. Bannon said on his podcast.

Supporters of DeSantis pushed back on suggestions — including from Trump allies — that the vaccine announcements were meant to outflank Trump ahead of a potential 2024 clash.

“If the left comes at him and says, you flipped because you want to be more anti-vaccine than Trump, he’s just gonna kill ’em with facts,” said Eric Anton, a GOP donor who said DeSantis would be one of his top choices for 2024. “If you want to call that political, then I think you’re too political.”

Even before DeSantis solidified his standing as the leading GOP alternative to Trump following a decisive reelection win, Republican strategists were quietly discussing Trump’s handling of the pandemic as a point of attack for DeSantis. But embracing a hostile position toward vaccines is not without political risk in the long run.

A Kaiser Family Foundation survey released Friday found 75 percent of U.S. adults have received at least one dose of a coronavirus vaccine, and half of adults are fully vaccinated and have received at least one booster shot. Most Republicans, too, are fully vaccinated, according to the survey, though they were less eager to get the updated booster than Democrats.

Public health experts voiced concern that DeSantis’s roundtable event could contribute to undermining public confidence in vaccines, especially for Florida seniors at high risk for severe covid.

“Initially his position was much more reasoned where he was actually saying vaccines are an important tool but maybe he didn’t think it was necessary to mandate that. That’s a reasonable debate to have,” said Jennifer Nuzzo, a professor of epidemiology and director of the Pandemic Center at the Brown University School of Public Health. “Where I feel that the argument has improperly gone is to try to impugn the safety of these vaccines. … I hate to think that people’s takeaway is going to be that these vaccines are not safe and effective, and that is just simply false.”

DeSantis began as a full-throated supporter of the vaccines before he started bashing them.

Throughout 2020, DeSantis repeatedly praised the Trump administration for working with industry to accelerate vaccine development, production and distribution, an effort known as “Operation Warp Speed.”

“I think they’re putting all hands on deck for it,” he said in one interview on Fox News Channel. “I applaud the president. I think that’s the right approach.”

As the vaccine became available in 2021, DeSantis defended the rollout against frustrations with initially scarce supplies. “I can tell you, we wish we have had more vaccine every week, but it’s just being produced,” he said in a February interview with Fox News. “So, I think, by and large, the Warp Speed team did a great job.”

DeSantis appeared in person at vaccination-related events, such as a February visit to a World War II veteran, a stadium appearance in Pahokee, Fla., and a March discussion highlighting “Florida’s status as a national leader on vaccine distribution.” His office also touted partnerships with companies such as Publix supermarkets, a vaccine site for law enforcement officers and a rural vaccination initiative.

In the face of new variants that threatened to blunt the effectiveness of vaccinations, DeSantis stood by the shots. “We’ve not seen any data or any evidence to suggest these vaccines are not effective,” he said at a February 2021 news conference.

As the Biden administration took over, DeSantis demanded that the federal government’s “sole focus” be on increasing vaccine supplies, which he promised his state would deliver right away. He also attributed the vaccines’ successes to Trump.

“I think the credit goes to President Trump,” he said in an interview with right-wing radio host Mark Levin in April 2021. “If we’d had a Biden, or heck, if we’d had some establishment Republican, they would have gotten drowned out in bureaucracy. This would never have gotten done.”

In another Fox News interview that month, DeSantis said the state’s efforts to encourage vaccinations, especially among seniors, succeeded in bringing down hospitalization rates. He was so enthusiastic about the vaccines’ effectiveness that he criticized the CDC for initially advising vaccinated people to continue wearing masks and social distancing.

“I think the messaging should be, ‘Get a vaccine because it’s good for you to do it. It works. You’re not going to have to have to be doing anything abnormal. You can live your life,’” DeSantis told a crowd at an April 2021 event in Lakeland. “That’s got to be what the message is.”

He also specifically endorsed the Moderna and Pfizer vaccines, which were developed using an innovative mRNA technology that DeSantis has more recently criticized in public statements. Back in March 2021, when production problems caused a shortage of the one-dose Johnson & Johnson vaccine, DeSantis encouraged people to get the mRNA shots instead. “If you have your heart set on Johnson & Johnson but you are able to get Pfizer or Moderna, I would say get it,” he said at the time.

Later in 2021, DeSantis’s office formally asked state lawmakers to approve $480 million in additional funding for the state’s health department, specifying that the money would support coronavirus testing, medical staffing and “Media and Education campaigns in response to COVID-19 and associated vaccinations.” The current state budget authorizes using leftover money for fighting covid, including testing and “immunization.”

“If you are vaccinated, fully vaccinated, the chance of you getting seriously ill or dying from covid is effectively zero,” DeSantis said in July 2021. “These vaccines are saving lives.”

DeSantis began his shift away from vaccines by opposing mandates, calling a special legislative session to ban employer requirements in 2021. By January 2022, after Trump was booed, DeSantis wouldn’t say whether he’d received a booster. “I’ve done whatever I did,” he said. “The normal shot, and that at the end of the day is people’s individual decisions about what they want to do.”

The governor appointed a state surgeon general, Joseph Ladapo, who advised young men against getting vaccinated, citing a preliminary analysis that was not signed or peer reviewed and that was denounced by medical and public health leaders. Ladapo has given interviews on podcasts associated with the groundless QAnon conspiracy theory — an extremist movement the FBI has designated as a domestic terrorism threat. Back in 2020, Ladapo participated in an event with a right-wing group that promoted false covid treatments.

“You expect disinformation from social media, but to actually have these folks holding government positions is really a slap in the face in the health-care profession,” said Pate, the retired health-care executive.

DeSantis invited Ladapo to present that discredited research at Wednesday’s event, before appointing him to lead a state panel that would issue its own guidance to rival the CDC’s. The other panel members, introduced at the event, are prominent critics of the vaccines. They include the authors of a controversial open letter calling for lifting pandemic restrictions and letting the virus spread to achieve “herd immunity,” as well as an emergency room physician whose studies on adverse reactions to the vaccines have been rebutted by experts. At DeSantis’s prompting, the ER doctor said calling the vaccines safe and effective is “a lie. It has to be.”

At the event, DeSantis also announced a petition to the Florida Supreme Court to establish a grand jury to investigate fraud related to the vaccines. The formal petition cited government and company statements about the vaccines’ protection against infection over time. But instead of understanding those statements as reflecting evolving scientific evidence and resistant new variants, the petition alleges a conspiracy.

“It is impossible to imagine that so many influential individuals came to this view on their own,” reads the petition, signed by DeSantis. “Rather, it is likely that individuals and companies with an incentive to do so created these perceptions for financial gain.”

In a statement, Pfizer said regulatory agencies around the world approved the company’s vaccine based on independent evaluations of scientific data on safety and efficacy, confirmed by real-world studies. “Over the course of this deadly pandemic, mRNA vaccines have saved hundreds of thousands of lives, tens of billions of dollars in health care costs, and enabled people worldwide to go about their lives more freely,” the company said.

Nuzzo, the Brown epidemiologist, said the vaccines’ safety has been proven by the billions of doses delivered worldwide. There are rare cases of heart inflammation in young men that scientists are working to avoid with measures such as spacing out doses.

“Those are reasonable, science-based questions to have,” she said. “But when dressed as, ‘I’m going to ask for a legal investigation, that was just irresponsible. … You gave a national platform to them to basically advance the goal of anti-vaxxers.”

Hannah Knowles, Fenit Nirappil and Scott Clement contributed to this report.

Read original article here

A Compound That Reverses Gut Inflammation Developed

Summary: Researchers have developed a new compound, dubbed FexD, that can prevent and reverse inflammation in mouse models of inflammatory bowel disease.

Source: Salk Institute

A drug developed by Salk Institute researchers acts like a master reset switch in the intestines. The compound, called FexD, has previously been found to lower cholesterol, burn fat, and ward off colorectal cancer in mice.

Now, the team reports in Proceedings of the National Academy of Sciences on December 12, 2022, that FexD can also prevent and reverse intestinal inflammation in mouse models of inflammatory bowel disease.

“The Salk-developed drug FexD provides a new way to restore balance to the digestive system and treat inflammatory diseases that are currently very difficult to manage,” says senior author and Salk Professor Ronald Evans, director of Salk’s Gene Expression Laboratory and March of Dimes Chair in Molecular and Developmental Biology.

Inflammatory bowel disease (IBD), which includes both Crohn’s disease and ulcerative colitis, is characterized by an excess of immune cells and inflammatory signaling molecules known as cytokines in the gut.

Existing treatments, which mostly work by either suppressing the entire immune system or by targeting individual cytokines, are only effective for some patients and carry a host of side effects.

For more than two decades, Evans’ lab has studied Farnesoid X receptor (FXR), a master regulator protein that senses the bile acids delivered to the digestive system to help digest food and absorb nutrients.

When FXR detects a shift in bile acids at the beginning of a meal, it prepares the body for an influx of food by flipping on and off dozens of cellular programs related to digestion, blood sugar, and fat metabolism.

In 2015, Evans and his colleagues developed a pill called fexaramine that activates FXR in the gut. The pill, they initially showed, can stop weight gain and control blood sugar in mice.

In 2019, they showed that FexD—an updated version of fexaramine—also prevented cancer-associated changes to stem cells in the gut. Their work suggested that FXR also played a role in regulating inflammation.

“Every time you eat, you’re causing small amounts of inflammation in your gut as your intestinal cells encounter new molecules. FXR makes sure inflammation stays under control during normal feeding,” says Senior Staff Scientist Michael Downes, co-corresponding author of the new paper.

In the new work, Evans’ group discovered that activating FXR can be used to ease symptoms in inflammation-driven diseases. When the researchers gave mice with IBD a daily dose of oral FexD, either before or after the onset of intestinal inflammation, the drug prevented or treated the inflammation.

The compound, called FexD, has previously been found to lower cholesterol, burn fat, and ward off colorectal cancer in mice. Image is in the public domain

By activating FXR, FexD reduced the infiltration of a class of highly inflammatory immune cells called innate lymphoid cells. In turn, levels of cytokines already implicated in IBD decreased to levels normally seen in healthy mice.

See also

“When we activate FXR, we restore appropriate signaling pathways in the gut, bringing things back to a homeostatic level,” says Senior Research Scientist Annette Atkins, co-author of the study.

Since FXR acts more like a reset button than an off switch for the immune system, cytokines are not completely blocked by FexD. This means that the immune system continues functioning in a normal way after a dose of FexD.

The compound still must be optimized for use in humans and tested in clinical trials, but the researchers say their findings provide important information about the complex links between gut health and inflammation and could eventually lead to an IBD therapeutic.

“In people with IBD, our strategy could potentially be very effective at preventing flare-ups and as a long-term maintenance drug,” says first author Ting Fu, previously a postdoctoral fellow at Salk and now an assistant professor at the University of Wisconsin-Madison.

Other authors of the paper include Yuwenbin Li, Tae Gyu Oh, Fritz Cayabyab, Nanhai He, Qin Tang, Morgan Truitt, Paul Medina, Mingxiao He, Ruth T. Yu, and Ye Zheng of Salk; and Sally Coulter and Christopher Liddle of the University of Sydney.

About this IBD and inflammation research news

Author: Press Office
Source: Salk Institute
Contact: Press Office – Salk Institute
Image: The image is in the public domain

Original Research: The findings will appear in PNAS

Read original article here

Killer robots: San Francisco reverses course on allowing police to use robots to kill amid public outcry



CNN
 — 

San Francisco officials voted Tuesday against a controversial measure that would have allowed police to deploy robots to use lethal force in extreme situations, reversing course after public outcry against the policy.

The about-face from the San Francisco Board of Supervisors comes a week after the board voted to approve the policy in an initial first reading vote, which prompted a protest at City Hall Monday, with some holding signs that said, “NO KILLER ROBOTS!”

On Tuesday, the board voted to remove text pertaining to robots and use of lethal force, according to Natalie Gee, the chief of staff for the board’s president. The text was initially included as part of a larger ordinance aiming to approve San Francisco Police Department funding and use of certain law enforcement equipment, Gee said.

The mayor still has to approve the general ordinance before it goes into effect.

Supervisor Hillary Ronen praised the vote in a statement, saying “common sense prevailed.”

“We stopped the use of killer robots in San Francisco today,” Ronen said. “The public outcry helped six Supervisors fully appreciate the gravity of last week’s vote and the numerous unanswered questions about both the ethics and practical implications of allowing police to use machines to kill human beings.”

Tuesday’s vote comes after the board voted 8-3 last week to approve the measure, which would have given police the authority to use ground-based robots to kill “when risk of loss of life to members of the public or officers is imminent and officers cannot subdue the threat after using alternative force options or de-escalation tactics,” according to the ordinance text.

Those in favor of deploying the robots have argued they can be useful in extreme or extraordinary situations, especially if it could prevent the loss of innocent lives.

In an interview last week with CNN, San Francisco Police Chief Bill Scott insisted the lethal function on the robots would only be used in such circumstances. He also noted that the robots would be operated by officers with specialized training.

Explosive charges could be added to the robots to breach fortified structures, or the robots could be deployed to “contact, incapacitate, or disorient” a dangerous suspect without risking the life of an officer, Scott said.

“These robots would be a last resort,” he said. “If we ever have to exercise that option, it either means lives, innocent lives, have already been lost, or in the balance, and this would be the only option to neutralize that person putting those lives at risk, or the person who has taken those lives.”

Still, officials and residents alike have spoken out against the policy, which needed to be approved by the board as required by a 2021 California law.

“The people of San Francisco have spoken loud and clear: There is no place for killer police robots in our city,” Supervisor Dean Preston said Tuesday after the vote. “We should be working on ways to decrease the use of force by local law enforcement, not giving them new tools to kill people.”

Read original article here

Australia reverses recognition of Jerusalem as Israel’s capital | Israel-Palestine conflict News

Foreign Minister Penny Wong says government ‘regrets’ decision made by previous administration and reiterates commitment to two-state solution.

Australia says it will no longer recognise West Jerusalem as the capital of Israel, reversing a decision taken by the government of former Prime Minister Scott Morrison in 2018.

“Today the Government has reaffirmed Australia’s previous and longstanding position that Jerusalem is a final status issue that should be resolved as part of any peace negotiations between Israel and the Palestinian people,” Foreign Minister Penny Wong said in a statement.

“This reverses the Morrison Government’s recognition of West Jerusalem as the capital of Israel.”

Wong reiterated that Australia’s embassy would remain in Tel Aviv and that Canberra was committed to a two-state solution “in which Israel and a future Palestinian state coexist, in peace and security, within internationally recognised borders”.

She added: “We will not support an approach that undermines this prospect.”

The status of Jerusalem is one of the biggest sticking points in attempts to reach a peace deal between Israel and the Palestinians.

Israel regards the entire city, including the eastern sector it annexed after the 1967 Middle East war, as its capital while Palestinian officials, with broad international backing, want occupied East Jerusalem as the capital of a future state they hope to establish in the occupied West Bank and the Gaza Strip.

Palestinian Authority hails the move

The Palestinian Authority hailed Australia’s move that will likely bring the Israeli-Palestinian issue into spotlight.

“We welcome Australia’s decision with regards to Jerusalem & its call for a two-state solution in accordance with international legitimacy,” the Palestinian Authority’s civil affairs minister, Hussein al-Sheikh, said on Twitter.

Sheikh hailed Australia’s “affirmation that the future of sovereignty over Jerusalem depends on the permanent solution based on international legitimacy”.

Shahram Akbarzadeh from Deakin University said that the Australia’s move will revive the international consensus on the status of Jerusalem.

“Australia was diverging from that consensus but now it’s coming back to it.

“It will definitely bring the issue, the Palestinian-Israeli dispute and the future of a two-state solution into spotlight,” he told Al Jazeera from Melbourne, adding that the international community has a big responsibility to address this long-standing problem.

“There is an international consensus that the status of Jerusalem should be handled, decided as part of a larger negotiation on the future of the two states within Israel and Palestine. They cannot be divorced from that matter.”

Al Jazeera’s Bernard Smith reporting from West Jerusalem said that while “little changes” with Wong’s announcement, it was nevertheless symbolic.

“Most countries recognise that the status the final status of Jerusalem is to be determined in talks on Palestinian statehood and Palestinians want East Jerusalem as their capital,” he added.

Israeli Prime Minister Yair Lapid on Tuesday sharply criticised Australia’s decision.

Lapid described the move as a “hasty response”, adding: “We can only hope that the Australian government manages other matters more seriously and professionally.

“Jerusalem is the eternal and united capital of Israel and nothing will ever change that,” the prime minister also said in a statement released by his office.

The Israeli foreign ministry said it had summoned the Australian ambassador to lodge a formal protest.

Former Australian Prime Minister Morrison announced his conservative government would recognise West Jerusalem as Israel’s capital after the United States went back on decades of policy by recognising the city and moving the US embassy there from Tel Aviv.

The Australian decision was widely criticised by pro-Palestinian groups as well as by the Labor party, which was then in opposition and promised to reverse the move if it was elected.

Read original article here

Elon Musk reverses course, says SpaceX will keep funding Ukraine Starlink service for free

Sign up for CNN’s Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.



CNN
 — 

US billionaire Elon Musk tweeted on Saturday that SpaceX will continue funding Starlink internet service in war-torn Ukraine, apparently reversing course after SpaceX asked the United States military to pick up the tab.

SpaceX’s Starlink satellite internet services have been a vital source of communication for the country’s military during the war with Russia, but as CNN exclusively reported earlier this week, SpaceX warned the Pentagon that it may stop funding the service in Ukraine unless the US military kicks in tens of millions of dollars per month, according to documents obtained by CNN.

The letter also requested that the Pentagon take over funding for Ukraine’s government and military use of Starlink, which SpaceX claims would cost more than $120 million for the rest of the year and could cost close to $400 million for the next 12 months. The report elicited a torrent of tweets from social media users both defending and criticizing the move.

A tweet from Musk’s verified account posted Saturday said, “The hell with it … even though Starlink is still losing money & other companies are getting billions of taxpayer $, we’ll just keep funding Ukraine govt for free.”

Since they first started arriving in Ukraine last spring, the Starlink satellite internet terminals made by Musk’s SpaceX have allowed Ukraine’s military to fight and stay connected even as cellular phone and internet networks have been destroyed in its war with Russia.

A Pentagon spokesperson said Friday afternoon that it had been in communication with SpaceX about the funding of the Starlink satellite communication product as well as other topics.

In response Saturday to a follower who replied to Musk’s tweet, “No good deed goes unpunished,” Musk said, “Even so, we should still do good deeds.”

Musk on Friday had doubled down on SpaceX’s request to the Pentagon in a series of tweets.

“SpaceX is not asking to recoup past expenses, but also cannot fund the existing system indefinitely *and* send several thousand more terminals that have data usage up to 100X greater than typical households. This is unreasonable,” read one post from Musk’s verified account.

He also said that in asking the Pentagon to pick up the bill for Starlink in Ukraine, he was following the advice of a Ukrainian diplomat who responded to Musk’s Ukraine peace plan earlier this month, before the letter was sent to the Pentagon, with: “F*** off.”

Ukraine’s ambassador to Germany, Andrij Melnyk, responded earlier this month to Musk’s claimed peace plan for Russia’s Ukraine war by saying: “F*** off is my very diplomatic reply to you @elonmusk.”

SpaceX’s suggestion that it would stop funding Starlink also came amid rising concern in Ukraine over Musk’s allegiance. Musk recently tweeted a controversial peace plan that would have Ukraine give up Crimea and control over the eastern Luhansk and Donetsk regions.

After Ukrainian President Volodymyr Zelensky raised the question of who Musk sides with, he responded that he “still very much support[s] Ukraine” but fears “massive escalation.”

One Ukrainian official, Mykhailo Podolyak, an adviser to Zelensky, appeared to extend an olive branch in a tweet posted Friday, writing, “Let’s be honest. Like it or not, @elonmusk helped us survive the most critical moments of war.”

“Business has the right to its own strategies,” Podolyak’s tweet read. “(We) will find a solution to keep #Starlink working. We expect that the company will provide stable connection till the end of negotiations.”

This story has been updated with additional information.



Read original article here

The Ultimate News Site